CMG Pharmaceuticals, a subsidiary of the CHA Hospital Group, is a company that leverages domestic and international hospital and R&D infrastructure to boost product manufacturing and distribution. In the medium to long term, it is expanding its pharmaceutical business scope to include the development of improved drugs, vaccine development, and licensing in-out projects.

Development of Improved Drugs : We are conducting research and development on various improved drugs, including the development of new formulations, combination drugs, extended-release formulations, and formulation modifications, with the goal of creating global improved drugs. Our R&D efforts are not limited to the domestic market but are also aimed at developing export products for global market entry. Generic Drug Development : Our R&D efforts are focused on not only developing first generic drugs but also on creating high-quality generic drugs. Recently, we have developed various generic drugs, including treatments for cardiovascular diseases and anti-inflammatory pain relievers. OTF (Oral Thin Film) : The advantages of the OTF formulation include improved patient compliance, reasonable pricing, and convenience in portability and administration. We are actively pursuing overseas expansion, having obtained FDA IND approval for aripiprazole, a treatment for schizophrenia, in the U.S. Recently, we completed bioequivalence studies and received regulatory approval from the Ministry of Food and Drug Safety for tadalafil and entecavir. For aripiprazole, we have completed domestic bioequivalence testing. In addition, we are leveraging our advanced technology to focus on the formulation of OTF products. Development of Synthetic New Drugs : Based on targeted cancer therapy technology, we are researching and developing synthetic new drugs with significantly superior efficacy compared to existing drugs, aiming to treat various types of cancer, including solid tumors, ovarian cancer, colorectal cancer, and lung cancer.

Public

Pharma, CDMO, CMO